Day One Biopharmaceutical... (DAWN)
8.19
0.07 (0.86%)
At close: Mar 27, 2025, 3:59 PM
8.18
-0.02%
After-hours: Mar 27, 2025, 05:36 PM EDT
Company Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers.
Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.
Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Day One Biopharmaceuticals Inc.
| Country | United States |
| IPO Date | May 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
Contact Details
Address: 395 Oyster Point Boulevard South San Francisco, California United States | |
| Website | https://dayonebio.com |
Stock Details
| Ticker Symbol | DAWN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001845337 |
| CUSIP Number | 23954D109 |
| ISIN Number | US23954D1090 |
| Employer ID | 83-2415215 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy Bender M.B.A., Ph.D. | Chief Executive Officer, President & Director |
| Charles N. York II, M.B.A. | Chief Operating Officer, Chief Financial Officer & Secretary |
| Jaa Roberson | Chief People Officer |
| John Stubenrauch Ph.D. | Chief Technology Officer |
| Adam Dubow J.D. | General Counsel and Chief Compliance Officer |
| Dr. Davy Chiodin Ph.D., Pharm.D. | Chief Development Officer |
| Dr. Elly Barry M.D. | Chief Medical Officer |
| Lauren Merendino M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 06, 2025 | 10-K/A | [Amend] Annual Report |
| Feb 28, 2025 | 3 | Filing |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 31, 2025 | 4 | Filing |